STOCK TITAN

[Form 4] Enovis CORP Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Enovis director Angela S. Lalor reported acquiring 742 shares of Enovis Corp (ENOV) on 09/30/2025 at a reported price of $0.00, increasing her direct beneficial ownership to 21,295 shares. The Form 4 shows the filing was signed by attorney-in-fact Brian P. Hanigan on 10/01/2025. The filing identifies Lalor as a director and indicates this is a single-person Form 4 filing. No derivative transactions or additional details are reported.

La direttrice di Enovis, Angela S. Lalor, ha riferito l'acquisto di 742 azioni della Enovis Corp (ENOV) il 30/09/2025 a un prezzo riportato di $0,00, aumentando la sua titolarità diretta a 21.295 azioni. Il modulo 4 mostra che la firma è stata apposta dall'avvocato-delegato Brian P. Hanigan il 01/10/2025. Il modulo identifica Lalor come amministratrice e indica che si tratta di una presentazione Form 4 a persona singola. Non sono riportate transazioni derivate né ulteriori dettagli.

La directora de Enovis, Angela S. Lalor, informó haber adquirido 742 acciones de Enovis Corp (ENOV) el 30/09/2025 a un precio reportado de $0,00, aumentando su propiedad beneficiosa directa a 21.295 acciones. El Formulario 4 muestra que la firma fue realizada por el mandatario autorizado Brian P. Hanigan el 01/10/2025. El formulario identifica a Lalor como directora y señala que se trata de una presentación de Form 4 de una sola persona. No se reportan transacciones derivadas ni otros detalles.

Enovis 이사인 Angela S. Lalor가 2025년 9월 30일 ENOV 주식 742주를 보고된 가격 0.00달러로 매입했다고 보고했고, 그녀의 직접적인 수익 소유 지분이 21,295주로 증가했습니다. Form 4에 따르면 서명은 2025년 10월 1일 대리인 Brian P. Hanigan에 의해 이루어졌습니다. 이 서류는 Lalor를 이사로 식별하며 단일인 Form 4 제출임을 명시합니다. 파생 거래나 추가 세부 정보는 보고되지 않았습니다.

La directrice d'Enovis, Angela S. Lalor, a déclaré avoir acquis 742 actions d'Enovis Corp (ENOV) le 30/09/2025 à un prix déclaré de 0,00 $, portant sa propriété bénéficiaire directe à 21 295 actions. Le Form 4 indique que le document a été signé par l'avocat-in-fait Brian P. Hanigan le 01/10/2025. Le formulaire identifie Lalor comme administratrice et précise qu'il s'agit d'une soumission Form 4 pour une seule personne. Aucune transaction dérivée ni autre détail n'est reporté.

Enovis-Direktorin Angela S. Lalor meldete den Erwerb von 742 Aktien der Enovis Corp (ENOV) am 30.09.2025 zu einem angegebenen Preis von 0,00 $, wodurch ihr direktes Beneficial Ownership auf 21.295 Aktien anstieg. Das Formular 4 zeigt, dass die Unterzeichnung vom Bevollmächtigten Brian P. Hanigan am 01.10.2025 erfolgt ist. Das Formular identifiziert Lalor als Direktorin und gibt an, dass dies eine einpersonige Form 4-Einreichung ist. Es werden keine derivativen Transaktionen oder weiteren Details berichtet.

أفادت مديرة Enovis، أنجيلا س. لالور، بأنها اشترت 742 سهماً من Enovis Corp (ENOV) في 30/09/2025 بسعر مُبلغ عنه قدره 0.00 دولار، مما زاد ملكيتها المفيدة المباشرة إلى 21,295 سهماً. يظهر النموذج 4 أن التوقيع تم من قبل الوكيل المحامي Brian P. Hanigan في 01/10/2025. يُعرِّف النموذج لالور كمديرة ويشير إلى أن هذا هو تقديم Form 4 لشخص واحد. لا تُذكر معاملات مشتقة أو تفاصيل إضافية.

Enovis 董事 Angela S. Lalor 报告在 2025-09-30 以披露价 0.00 美元买入 Enovis Corp (ENOV) 的 742 股,直接受益所有权增至 21,295 股。 Form 4 显示由代理人 Brian P. Hanigan 于 2025-10-01 签署。该表格将 Lalor 识别为董事,并指出这是单人 Form 4 申报。未报告衍生交易或其他细节。

Positive
  • None.
Negative
  • None.

Insights

TL;DR: A director reported a small non-derivative share acquisition, increasing direct holdings to 21,295 shares; transaction appears routine and non-material.

The Form 4 documents a 09/30/2025 acquisition of 742 common shares by director Angela S. Lalor at a reported price of $0.00, with total direct beneficial ownership of 21,295 shares following the transaction. There are no derivative securities reported and no price or value context beyond the $0.00 price field. For most investors this level of share movement by a director in isolation is unlikely to be material relative to company market capitalization, and the filing contains no additional corporate or compensatory detail.

TL;DR: Routine insider disclosure showing a director-level acquisition; disclosure compliance appears met, with no governance red flags in the filing.

The filing identifies Lalor as a director and reports the acquisition clearly on the Form 4, signed by an attorney-in-fact on 10/01/2025. The absence of derivative transactions and the straightforward reporting of beneficial ownership increases suggest standard compliance with Section 16 filing requirements. The $0.00 price field is noted as reported; the form does not provide explanatory text about transaction consideration.

La direttrice di Enovis, Angela S. Lalor, ha riferito l'acquisto di 742 azioni della Enovis Corp (ENOV) il 30/09/2025 a un prezzo riportato di $0,00, aumentando la sua titolarità diretta a 21.295 azioni. Il modulo 4 mostra che la firma è stata apposta dall'avvocato-delegato Brian P. Hanigan il 01/10/2025. Il modulo identifica Lalor come amministratrice e indica che si tratta di una presentazione Form 4 a persona singola. Non sono riportate transazioni derivate né ulteriori dettagli.

La directora de Enovis, Angela S. Lalor, informó haber adquirido 742 acciones de Enovis Corp (ENOV) el 30/09/2025 a un precio reportado de $0,00, aumentando su propiedad beneficiosa directa a 21.295 acciones. El Formulario 4 muestra que la firma fue realizada por el mandatario autorizado Brian P. Hanigan el 01/10/2025. El formulario identifica a Lalor como directora y señala que se trata de una presentación de Form 4 de una sola persona. No se reportan transacciones derivadas ni otros detalles.

Enovis 이사인 Angela S. Lalor가 2025년 9월 30일 ENOV 주식 742주를 보고된 가격 0.00달러로 매입했다고 보고했고, 그녀의 직접적인 수익 소유 지분이 21,295주로 증가했습니다. Form 4에 따르면 서명은 2025년 10월 1일 대리인 Brian P. Hanigan에 의해 이루어졌습니다. 이 서류는 Lalor를 이사로 식별하며 단일인 Form 4 제출임을 명시합니다. 파생 거래나 추가 세부 정보는 보고되지 않았습니다.

La directrice d'Enovis, Angela S. Lalor, a déclaré avoir acquis 742 actions d'Enovis Corp (ENOV) le 30/09/2025 à un prix déclaré de 0,00 $, portant sa propriété bénéficiaire directe à 21 295 actions. Le Form 4 indique que le document a été signé par l'avocat-in-fait Brian P. Hanigan le 01/10/2025. Le formulaire identifie Lalor comme administratrice et précise qu'il s'agit d'une soumission Form 4 pour une seule personne. Aucune transaction dérivée ni autre détail n'est reporté.

Enovis-Direktorin Angela S. Lalor meldete den Erwerb von 742 Aktien der Enovis Corp (ENOV) am 30.09.2025 zu einem angegebenen Preis von 0,00 $, wodurch ihr direktes Beneficial Ownership auf 21.295 Aktien anstieg. Das Formular 4 zeigt, dass die Unterzeichnung vom Bevollmächtigten Brian P. Hanigan am 01.10.2025 erfolgt ist. Das Formular identifiziert Lalor als Direktorin und gibt an, dass dies eine einpersonige Form 4-Einreichung ist. Es werden keine derivativen Transaktionen oder weiteren Details berichtet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Lalor Angela S

(Last) (First) (Middle)
2711 CENTERVILLE ROAD
SUITE 400

(Street)
WILMINGTON DE 19808

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Enovis CORP [ ENOV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock, par value $0.001 09/30/2025 A 742 A $0.00 21,295 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Brian P. Hanigan, attorney-in-fact 10/01/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Enovis Corp

NYSE:ENOV

ENOV Rankings

ENOV Latest News

ENOV Latest SEC Filings

ENOV Stock Data

1.75B
56.25M
1.57%
121.34%
12.07%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
WILMINGTON